Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
86.66
+0.77 (+0.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Got $5,000? These 3 Stocks Are Near Their 52-Week Lows and Are Underrated Buys
February 10, 2024
These stocks all trade at less than 17 times their future expected earnings.
Via
The Motley Fool
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
February 08, 2024
AZN earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 08, 2024
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results.
Via
Benzinga
Earnings Scheduled For February 8, 2024
February 08, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.
Via
Benzinga
Earnings Outlook For AstraZeneca
February 07, 2024
Via
Benzinga
Check Out What Whales Are Doing With AZN
January 17, 2024
Via
Benzinga
How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month
February 08, 2024
Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.
Via
Investor's Business Daily
AstraZeneca Stock Tumbles After Q4 Performance - Here's Why
February 08, 2024
AstraZeneca Q4 2023: $12.02 billion sales, 7% Y/Y growth, fueled by global demand for cancer drugs. Excluding COVID-19 meds, revenue rises 16%. CEO Soriot projects low double-digit growth in 2024.
Via
Benzinga
Exposures
COVID-19
AstraZeneca Downgraded On "Underwhelming" Q4 Earnings
February 08, 2024
AZN stock took a header early Thursday after a mixed Q4 report and a downgrade to sell on "thoroughly underwhelming" results.
Via
Investor's Business Daily
NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?
February 05, 2024
The relaunch of Wegovy last year caused a mad dash by weight loss stocks to compete for market leadership in anti-obesity drugs.
Via
InvestorPlace
History Says the Nasdaq Will Keep Soaring in 2024. Here's the Surprising Megacap Stock Wall Street Thinks Will Be the Biggest Winner.
February 03, 2024
Hint: It's not Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, or Tesla.
Via
The Motley Fool
Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry
January 09, 2024
Via
Benzinga
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares
January 31, 2024
Eli Lilly to report strong Q4 earnings thanks to successful diabetes treatments, while rivals like Novo Nordisk and Pfizer are also vying for a share of the weight-loss market.
Via
Benzinga
3 No-Brainer Stocks to Buy With $500 Right Now
January 31, 2024
A reasonably modest amount of money can go a long way when it's put to work in industry-leading businesses.
Via
The Motley Fool
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.
Via
Benzinga
3 Magnificent Stocks to Buy and Hold Forever
January 27, 2024
Many investors will want to consider owning these stocks for a long time.
Via
The Motley Fool
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
January 23, 2024
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.
Via
Benzinga
Exposures
Product Safety
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
January 20, 2024
Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech...
Via
Talk Markets
AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study
January 19, 2024
Explore results from AstraZeneca's EMERALD-1 Phase 3 trial on Imfinzi for unresectable hepatocellular carcinoma. Statistically significant improvement in progression-free survival with Imfinzi plus...
Via
Benzinga
Are You Kidding Me? 3 Meme Stocks You Should Have Already Sold
January 15, 2024
Be sure to sell these meme stocks as they represent fundamentally weak businesses that will continue to erode in value.
Via
InvestorPlace
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
January 12, 2024
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed...
Via
Benzinga
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
January 12, 2024
There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.
Via
Investor's Business Daily
Oxford University Kicks off Human Study for AstraZeneca's COVID-19 Vaccine Technology in Nipah Virus Defense
January 11, 2024
Join the fight against Nipah virus! Oxford Vaccine Group launches groundbreaking ChAdOx1 NipahB vaccine trial, targeting the deadly virus. 51 participants aged 18-55. Funded by CEPI. Help combat Nipah...
Via
Benzinga
Exposures
COVID-19
4 Superior Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
January 06, 2024
The growth-fueled Nasdaq Composite is 9% below its record high, meaning amazing deals are still hiding in plain sight.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.
Via
Benzinga
Exposures
Product Safety
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
January 05, 2024
Key Takeaways: AstraZeneca will acquire Chinese cell therapy maker Gracell for up to $1.2 billion, representing an 86% premium to the company’s pre-announcement share price
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
7 Dividend-Paying Stocks To Add To Your Income Portfolio In 2024
January 03, 2024
These are the undervalued and fundamentally strong dividend-paying stocks to buy for high total returns in the next 24 to 36 months.
Via
InvestorPlace
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today
January 02, 2024
VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.